Targeted resequencing through hybrid selection on custom microarrays is a direct and cost-effective route to address numerous genomic questions, including cancer genetics, said CSHL researcher Emily Hodges, Ph.D., the first author of the paper. The convenience of the microarrays, combined with off-the-shelf reagents, represent a resequencing platform that can easily be adapted or reconfigured to address the individual interests of the investigator.
We are very pleased to have worked with Dr. Gregory Hannon’s laboratory at CSHL, said co-author Andy Bhattacharjee, Ph.D., of Agilent’s Life Sciences Division. The on-array capture method is simple, versatile and robust, and will effectively address an important need in next-generation sequencing sample preparation. Furthermore, the customizability and simplicity of array design is easily replicated to capture portions of other sequenced eukaryotic genomes.